Prevalence of NAFLD Set to Increase to 34.3 Percent in 2050
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 20, 2023 -- The burden of nonalcoholic fatty liver disease (NAFLD) is predicted to continue increasing, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, held from Nov. 10 to 14 in Boston.
Phuc Le, Ph.D., M.D., from the Cleveland Clinic, and colleagues developed an agent-based state transition model that included two components with a yearly cycle, simulating the U.S. population from the year 2000 based on Census data and tracking the natural history of NAFLD progression in adults encompassing 14 distinct health states.
Model validation demonstrated a close match between predicted outcomes from 2000 to 2018 and published data. The researchers found that the model predicted a steady increase in the prevalence of NAFLD among U.S. adults from 2020 to 2050 (27.8 to 34.3 percent). The proportion of nonalcoholic steatohepatitis is expected to increase from 20.0 to 21.8 percent among NAFLD cases. For people aged 18 to 29 years, prevalence should remain relatively stable, but significant increases are projected in other age groups. From 2020 to 2050, the proportion of NAFLD patients who develop cirrhosis is projected to increase from 1.9 to 3.1 percent; liver-related deaths are expected to increase from 0.4 to 1.0 percent of all deaths. NAFLD is projected to cause 19,300 new cases of hepatocellular carcinoma by 2050 and 4,200 new cases of liver transplant per year, representing a significant increase from 10,400 and 1,700 cases, respectively, in 2020.
"With diabetes and obesity rates on the rise, metabolic dysfunction-associated steatotic liver disease is expected to become the leading reason for liver transplants in the United States," Le said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
MRE-Liver Stiffness Measure Better for Varices in NAFLD Cirrhosis
WEDNESDAY, May 8, 2024 -- For patients with obesity and nonalcoholic fatty liver disease (NAFLD) compensated cirrhosis (CC), liver stiffness measurement (LSM) by magnetic...
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter...
NASH Resolution Increased, Improvement of Fibrosis Seen With Resmetirom
THURSDAY, Feb. 8, 2024 -- For patients with nonalcoholic steatohepatitis (NASH) and fibrosis stage F1B, F2, or F3, 80- and 100-mg resmetirom is better than placebo, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.